A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Abstract Background Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis. Volixibat inhibits bile acid reuptake via the apical sodium bile acid transporter located on the luminal surface of the ileum. The resulting increase in bile acid synthesis from cho...

Full description

Bibliographic Details
Main Authors: Melissa Palmer, Lee Jennings, Debra G. Silberg, Caleb Bliss, Patrick Martin
Format: Article
Language:English
Published: BMC 2018-03-01
Series:BMC Pharmacology and Toxicology
Subjects:
Volixibat
SHP626
LUM002
Non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease
Apical sodium-dependent bile acid transporter (ASBT)
Online Access:http://link.springer.com/article/10.1186/s40360-018-0200-y

Similar Items

Similar Items